Ismail M, Parikh N, Zhai M, Elaskandrany MA, Wang W. Levofloxacin-Induced Hepatotoxicity in Patients With Legionnaires' Disease: Implications and Management.
Cureus 2023;
15:e51248. [PMID:
38283526 PMCID:
PMC10821815 DOI:
10.7759/cureus.51248]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/28/2023] [Indexed: 01/30/2024] Open
Abstract
Legionnaires' disease (LD), caused by the Legionella bacterium, primarily manifests as pneumonia and could result in a spectrum of clinical severity. As treatment necessitates the use of antibiotics, levofloxacin, a fluoroquinolone, is a commonly preferred option due to its broad-spectrum activity. However, the potential side effects of levofloxacin, including rare instances of hepatotoxicity, introduce a therapeutic challenge. This case report explores the association between levofloxacin and hepatotoxicity and its implications for treating LD.
Collapse